Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida School of Medicine, Tampa.
Arterioscler Thromb Vasc Biol. 2022 Feb;42(2):205-222. doi: 10.1161/ATVBAHA.121.316798. Epub 2021 Dec 9.
We sought to determine how endothelial cell (EC) expression of the activating k-Ras (kirsten rat sarcoma 2 viral oncogene homolog) mutation, k-RasV12, affects their ability to form lumens and tubes and interact with pericytes during capillary assembly Approach and Results: Using defined bioassays where human ECs undergo observable tubulogenesis, sprouting behavior, pericyte recruitment to EC-lined tubes, and pericyte-induced EC basement membrane deposition, we assessed the impact of EC k-RasV12 expression on these critical processes that are necessary for proper capillary network formation. This mutation, which is frequently seen in human ECs within brain arteriovenous malformations, was found to markedly accentuate EC lumen formation mechanisms, with strongly accelerated intracellular vacuole formation, vacuole fusion, and lumen expansion and with reduced sprouting behavior, leading to excessively widened tube networks compared with control ECs. These abnormal tubes demonstrate strong reductions in pericyte recruitment and pericyte-induced EC basement membranes compared with controls, with deficiencies in fibronectin, collagen type IV, and perlecan deposition. Analyses of signaling during tube formation from these k-RasV12 ECs reveals strong enhancement of Src (Src proto-oncogene, non-receptor tyrosine kinase), Pak2 (P21 [RAC1 (Rac family small GTPase 1)] activated kinase 2), b-Raf (v-raf murine sarcoma viral oncogene homolog B1), Erk (extracellular signal-related kinase), and Akt (AK strain transforming) activation and increased expression of PKCε (protein kinase C epsilon), MT1-MMP (membrane-type 1 matrix metalloproteinase), acetylated tubulin and CDCP1 (CUB domain-containing protein 1; most are known EC lumen regulators). Pharmacological blockade of MT1-MMP, Src, Pak, Raf, Mek (mitogen-activated protein kinase) kinases, Cdc42 (cell division cycle 42)/Rac1, and Notch markedly interferes with lumen and tube formation from these ECs.
Overall, this novel work demonstrates that EC expression of k-RasV12 disrupts capillary assembly due to markedly excessive lumen formation coupled with strongly reduced pericyte recruitment and basement membrane deposition, which are critical pathogenic features predisposing the vasculature to develop arteriovenous malformations.
我们旨在确定内皮细胞 (EC) 中激活的 k-Ras(kirsten 大鼠肉瘤 2 病毒癌基因同源物)突变,k-RasV12 的表达如何影响其形成管腔和小管的能力,并在毛细血管组装过程中与周细胞相互作用。
使用已定义的生物测定法,其中人 EC 经历可观察到的小管发生、发芽行为、周细胞募集到 EC 衬里管、周细胞诱导的 EC 基底膜沉积,我们评估了 EC k-RasV12 表达对这些对于适当的毛细血管网络形成至关重要的过程的影响。这种突变在脑动静脉畸形中经常在人类 EC 中发现,它明显加剧了 EC 管腔形成机制,表现为强烈加速的细胞内空泡形成、空泡融合和管腔扩张,以及发芽行为减少,导致与对照 EC 相比,管腔网络过度变宽。与对照相比,这些异常管表现出周细胞募集和周细胞诱导的 EC 基底膜的强烈减少,纤连蛋白、IV 型胶原和 perlecan 沉积不足。对这些 k-RasV12EC 形成管腔过程中的信号分析表明,Src(Src 原癌基因,非受体酪氨酸激酶)、Pak2(P21[RAC1(Rac 家族小 GTP 酶 1)]激活激酶 2)、B-Raf(v-raf 鼠肉瘤病毒癌基因同源物 B1)、Erk(细胞外信号相关激酶)和 Akt(AK 株转化)的激活以及 PKCε(蛋白激酶 C epsilon)、MT1-MMP(膜型 1 基质金属蛋白酶)、乙酰化微管和 CDCP1(含 CUB 结构域的蛋白 1;大多数是已知的 EC 管腔调节剂)表达的增加。MT1-MMP、Src、Pak、Raf、Mek(丝裂原激活蛋白激酶)激酶、Cdc42(细胞分裂周期 42)/Rac1 和 Notch 的药理学阻断显著干扰这些 EC 的管腔和管腔形成。
总的来说,这项新工作表明,EC 中 k-RasV12 的表达由于与强烈减少的周细胞募集和基底膜沉积相结合的明显过度管腔形成而破坏了毛细血管组装,这是导致血管发育成动静脉畸形的关键致病特征。